News Allergan abandons women’s health sale plan as profit slumps Shares in Allergan fell after the company said it had swung to a loss in the last quarter of 2018, and forecast 2019 revenues below analyst expectations.
News UK's KaNDy Therapeutics funds mid-stage trial of HRT 'replac... Biotech hopes for IPO or big pharma deal to fund phase 3
News FDA rejects Allergan's fibroids drug, citing liver safety co... European regulators have already restricted use
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.